Prognostic factors in cancer patients infected with SARS-CoV-2: a Latin American country results


Por: Ruiz-Garcia, Erika, Pena-Nieves, Adriana, Alegria-Banos, Jorge, Cornejo-Juarez, Patricia, Meneses-Garcia, Abelardo, Rivera Rivera, Samuel, Jose Sanchez, Juan, Gerson-Cwilich, Raquel, Shveid Gerson, Daniela, Medina Franco, Heriberto, Alejandra Buerba, Gabriela, Acosta Espinoza, Alicia, Valencia Mijares, Norma, Fernandez-Figueroa, Edith A., Vazquez, Roberto A., Vilar-Compte, Diana, De la Rosa Martinez, Daniel, Valdez-Reyes, Melissa, Martinez Sanchez, Yazmin, Moises Tavera, Diego, Viveros Aguilar, Eloina, Camarin, Efrain, Villegas, Diana, Noguez, Alejandro, Ortiz Brizuela, Edgar, Mendez-Calderillo, Viridiana, Pacheco Perez, Rodrigo, Feregrino Arreola, Juan Pablo, Burguete Torres, Alan, Vidal Gutierrez, Oscar, Anorve Bailon, Denisse, Castillo Gutierrez, Erika, Luna Merlos, Pedro, Rivera Marquez, Raul, Jimenez Lopez, Jose Carlos, del Castillo Balderas, Gabriela Alvarez, ONCOVID-MEX Grp

Publicada: 1 sep 2021
Categoría: Medicine (miscellaneous)

Resumen:
Purpose: The aim of this study was to evaluate the demographic characteristics, clinical and pathological factors, and the outcome of cancer and COVID-19 patients in Mexico. Patients and methods: A prospective, multicentric study was performed through a digital platform to have a national registry of patients with cancer and positive SARS-CoV-2 test results through reverse transcription quantitative polymerase chain reaction (RT-qPCR). We performed the analysis through a multivariate logistic regression model and Cox proportional hazard model. Results: From May to December 2020, 599 patients were registered with an average age of 56 years with 59.3% female; 27.2% had hypertension. The most frequent diagnoses were breast cancer (30.4%), lymphoma (14.7%), and colorectal cancer (14.0%); 72.1% of patients had active cancer and 23.5% of patients (141/599) were deceased, the majority of which were men (51.7%). This study found that the prognostic factors that reduced the odds of death were gender (OR = 0.42, p = 0.031) and oxygen saturation (OR = 0.90, p = 0.0001); meanwhile, poor ECOG (OR = 5.4, p = 0.0001), active disease (OR = 3.9, p = 0.041), dyspnea (OR = 2.5, p = 0.027), and nausea (OR = 4.0, p = 0.028) increased the odds of death. In the meantime, the factors that reduce survival time were age (HR = 1.36, p = 0.035), COPD (HR = 8.30, p = 0.004), having palliative treatment (HR = 10.70, p = 0.002), and active cancer without treatment (HR = 8.68, p = 0.008). Conclusion: Mortality in cancer patients with COVID-19 is determined by prognostic factors whose identification is necessary. In our cancer population, we have observed that being female, younger, non-COPD, with non-active cancer, good performance status, and high oxygen levels reduce the probability of death.

Filiaciones:
Ruiz-Garcia, Erika:
 Inst Nacl Cancerol, Dept Med Oncol, Av San Fernando 22, Mexico City 14080, DF, Mexico

 Inst Nacl Cancerol, Translat Med Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico

Pena-Nieves, Adriana:
 Inst Nacl Cancerol, Translat Med Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico

Alegria-Banos, Jorge:
 Ctr Oncol Hosp Med Sur, Mexico City, DF, Mexico

 Univ La Salle, Fac Ciencias Quim, Mexico City, DF, Mexico

Cornejo-Juarez, Patricia:
 Inst Nacl Cancerol, Dept Infect Dis, Av San Fernando 22, Mexico City 14080, DF, Mexico

Meneses-Garcia, Abelardo:
 Inst Nacl Cancerol, Translat Med Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico

Rivera Rivera, Samuel:
 IMSS, Dept Med Oncol, Hosp Oncol CM SXXI, Mexico City, DF, Mexico

Jose Sanchez, Juan:
 IMSS, Dept Med Oncol, Hosp Oncol CM SXXI, Mexico City, DF, Mexico

Gerson-Cwilich, Raquel:
 Ctr Med ABC, Dept Med Oncol, Mexico City, DF, Mexico

Shveid Gerson, Daniela:
 Ctr Med ABC, Dept Med Oncol, Mexico City, DF, Mexico

Medina Franco, Heriberto:
 Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Surg, Mexico City, DF, Mexico

Alejandra Buerba, Gabriela:
 Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Surg, Mexico City, DF, Mexico

Acosta Espinoza, Alicia:
 Hosp ISSSTE ISSSTECALI, Mexicali, Baja California, Mexico

Valencia Mijares, Norma:
 IMSS, Hosp Reg Alta Especialidad Oaxaca, UMAA 1, Oaxaca, Oaxaca, Mexico

Fernandez-Figueroa, Edith A.:
 Inst Nacl Med Genom, Computat & Integrat Genom, Mexico City, DF, Mexico

Vazquez, Roberto A.:
 Univ La Salle, Fac Ingn, Mexico City, DF, Mexico

Vilar-Compte, Diana:
 Inst Nacl Cancerol, Dept Infect Dis, Av San Fernando 22, Mexico City 14080, DF, Mexico

 Inst Nacl Cancerol, Hosp Epidemiol, Mexico City, DF, Mexico

De la Rosa Martinez, Daniel:
 Univ Nacl Autonoma Mexico, Fac Med, Plan Estudios Combinados Med PECEM, Mexico City, DF, Mexico

Valdez-Reyes, Melissa:
 Inst Nacl Cancerol, Translat Med Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico

Martinez Sanchez, Yazmin:
 IMSS, Hosp Epidemiol, Hosp Oncol CM SXXI, Mexico City, DF, Mexico

Moises Tavera, Diego:
 IMSS, Hosp Epidemiol, Hosp Oncol CM SXXI, Mexico City, DF, Mexico

Viveros Aguilar, Eloina:
 IMSS, Dept Med Oncol, Hosp Oncol CM SXXI, Mexico City, DF, Mexico

Camarin, Efrain:
 Ctr Med ABC, Dept Med Oncol, Mexico City, DF, Mexico

Villegas, Diana:
 Ctr Med ABC, Dept Med Oncol, Mexico City, DF, Mexico

Noguez, Alejandro:
 Ctr Med ABC, Dept Med Oncol, Mexico City, DF, Mexico

Ortiz Brizuela, Edgar:
 Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico

Mendez-Calderillo, Viridiana:
 Hosp Med Celaya, Guanajuato, Mexico

Pacheco Perez, Rodrigo:
 Hosp Reg ISSSTE, Merida, Yucatan, Mexico

Feregrino Arreola, Juan Pablo:
 Hosp H Queretaro, Queretaro, Mexico

Burguete Torres, Alan:
 Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose E Gonzalez, San Nicolas De Los Garza, Nuevo Leon, Mexico

Vidal Gutierrez, Oscar:
 Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose E Gonzalez, San Nicolas De Los Garza, Nuevo Leon, Mexico

Anorve Bailon, Denisse:
 ISSSTE, Hosp Reg Gen Ignacio Zaragoza, Mexico City, DF, Mexico

Castillo Gutierrez, Erika:
 CMN Adolfo Ruiz Cortines Veracruz, UMAE Hosp Especialidades 14, Veracruz, Veracruz, Mexico

Luna Merlos, Pedro:
 Ctr Oncol Hosp Med Sur, Mexico City, DF, Mexico

Rivera Marquez, Raul:
 Hosp Gen Reg 1 IMSS, Obregon, Sonora, Mexico

Jimenez Lopez, Jose Carlos:
 Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City, DF, Mexico

del Castillo Balderas, Gabriela Alvarez:
 Univ La Salle, Fac Ingn, Mexico City, DF, Mexico
ISSN: 20406231





THERAPEUTIC ADVANCES IN CHRONIC DISEASE
Editorial
SAGE Publications Inc., 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND, Estados Unidos America
Tipo de documento: Article
Volumen: 12 Número:
Páginas:
WOS Id: 000703270600001
ID de PubMed: 34729153
imagen gold

MÉTRICAS